BACKGROUND: The 21-gene recurrence score (RS) assay (Oncotype DX) has become a cornerstone for guiding adjuvant systemic therapy in early-stage hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer. This evidence concerns the gene NR4A1 and breast carcinoma.